A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Status:
Completed
Trial end date:
2020-06-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab
(CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.